JP2012136518A5 - - Google Patents

Download PDF

Info

Publication number
JP2012136518A5
JP2012136518A5 JP2011280781A JP2011280781A JP2012136518A5 JP 2012136518 A5 JP2012136518 A5 JP 2012136518A5 JP 2011280781 A JP2011280781 A JP 2011280781A JP 2011280781 A JP2011280781 A JP 2011280781A JP 2012136518 A5 JP2012136518 A5 JP 2012136518A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
lyophilized
composition according
lyophilized immunogenic
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011280781A
Other languages
English (en)
Japanese (ja)
Other versions
JP6097478B2 (ja
JP2012136518A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012136518A publication Critical patent/JP2012136518A/ja
Publication of JP2012136518A5 publication Critical patent/JP2012136518A5/ja
Application granted granted Critical
Publication of JP6097478B2 publication Critical patent/JP6097478B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011280781A 2010-12-22 2011-12-22 黄色ブドウ球菌(Staphylococcusaureus)抗原の安定な免疫原性組成物 Expired - Fee Related JP6097478B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22
US61/426,476 2010-12-22

Publications (3)

Publication Number Publication Date
JP2012136518A JP2012136518A (ja) 2012-07-19
JP2012136518A5 true JP2012136518A5 (2) 2015-01-29
JP6097478B2 JP6097478B2 (ja) 2017-03-15

Family

ID=45444677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011280781A Expired - Fee Related JP6097478B2 (ja) 2010-12-22 2011-12-22 黄色ブドウ球菌(Staphylococcusaureus)抗原の安定な免疫原性組成物

Country Status (18)

Country Link
US (1) US20130259896A1 (2)
EP (2) EP2654784B1 (2)
JP (1) JP6097478B2 (2)
KR (2) KR20130114210A (2)
CN (1) CN103826656B (2)
AU (1) AU2011346535B2 (2)
BR (1) BR112013016153A2 (2)
CA (1) CA2819120C (2)
DK (2) DK3150222T3 (2)
ES (2) ES2614815T3 (2)
HU (2) HUE047263T2 (2)
IL (1) IL226793B (2)
MX (1) MX350170B (2)
PL (2) PL3150222T3 (2)
PT (2) PT2654784T (2)
RU (1) RU2570730C2 (2)
SI (2) SI2654784T1 (2)
WO (1) WO2012085872A2 (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PL2575870T3 (pl) * 2010-06-04 2017-05-31 Wyeth Llc Preparaty szczepionek
AU2012266880A1 (en) * 2011-03-16 2013-10-03 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US10195262B2 (en) * 2013-12-04 2019-02-05 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
PL3129001T3 (pl) * 2014-04-10 2020-06-29 Asit Biotech S.A. Preparat alergenów wolny od hsp
CN110996992A (zh) * 2017-08-16 2020-04-10 默沙东公司 肺炎球菌缀合物疫苗制剂
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
KR102058961B1 (ko) * 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1034277B1 (en) 1997-11-26 2012-06-27 Inhibitex, Inc. Extracellular matrix-binding proteins from Staphylococcus aureus
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
ES2322409T3 (es) * 1998-08-31 2009-06-19 Inhibitex, Inc. Vacunas multicomponentes contra staphylococcus aureus.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
RU2413520C2 (ru) 2000-06-08 2011-03-10 Интерселл Аг Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
MXPA03011701A (es) 2001-06-15 2004-12-06 Nhibitex Inc Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
MX2009004862A (es) * 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس

Similar Documents

Publication Publication Date Title
JP2012136518A5 (2)
RU2013128277A (ru) СТАБИЛЬНЫЕ ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
JP2016520075A5 (2)
JP2014530010A5 (2)
JP2016065060A5 (2)
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP2012515221A5 (2)
JP2013543505A5 (2)
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
WO2007130493A3 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
HRP20160276T1 (hr) Pripravci za imuniziranje protiv bakterije staphylococcus aureus
JP2015231997A5 (2)
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
HRP20210242T1 (hr) Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
JP2014040441A5 (2)
HRP20160434T1 (hr) Formulacija abeta-protutijela
JP2012521201A5 (2)
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
RU2015122368A (ru) Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
EA201490804A1 (ru) Препараты этанерцепта, стабилизированные хлоридом натрия
NO20090177L (no) Vaksiner for malaria
JP2014525429A5 (2)
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds